life scienc
bearish pharma outlook move pipelin
present start outweigh macro tailwind
tuesday market-open report financi result in-
line forecast pharma segment actelion portfolio
begun significantli disappoint expect remicad eros
acceler mainstay franchis imbruvica begin
moder growth major discuss point investor
whether neg pharma thesi trump posit macro factor
continu think despit tailwind tax reform help
stock overal stock market end day
pharma drive total profit gener compani
reiter sell rate pt
forecast peak recent pharma growth expect
mirror imag remaind year wherebi
growth moder significantli forecast call
pharma oper growth
explicitli includ approv apalutamid
within forecast drug model insid report
remicad eros start becom impact deterior
price like affect overal compani gross margin management
note volum remicad gener steadi
come expens price declin pure hit
product margin best estim price eros
remicad neg impact overal compani gross margin
yoy
actelion pah portfolio seem fall apart cautiou thesi
start transact actelion pah portfolio
alreadi market leader would hard drive outsiz
growth face gener pah market overal
grow mid-single-digit yoy said yoy declin
sale actelion pah portfolio qoq well
expect yoy growth uptravi swamp
heavi loss tracleer within market
valuat price base ev/ sale sotp
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
bearish pharma outlook move pipelin
present start outweigh macro tailwind
flip script nanj legend biotech management state
first-half interest within
current class therapi join fray
chines biotech data anti-bcma multipl
myeloma continu think bluebird bio buy pt
better proven clinic product celgen celg neutral
acquisit juno therapeut
juno neutral
consolid number anti-bcma program could produc
effect clinic product note spend
within space light undertak new pursuit
higher spend materi within
latitud studi continu drive out-performance zytiga
gener competit make outlook short-liv expect
gener zytiga competit occur within us
call management indic expect gener
competit current stay gener
competit expir octob hatch-waxman
recent ipr rule affect timelin regardless zytiga
continu signific area out-performance
strong uptak treatment newli diagnos metastat
prostat cancer patient drive sale growth yoy
receiv acceler approv apalutamid
treatment patient non-metastat castrat resist
prostat cancer pdufa date april
apalutamid hail potenti best-in-class compound
follow zytiga sinc drug also came ucla lab
xtandi anoth second-gener androgen receptor antagonist
develop success approv would make first drug
class use earli stage diseas progress
manag expect drug acquir
cash mileston payment blockbust phase
studi also on-going patient metastat
current forecast sale apalutamid use
pppi base price zytiga figur
assum non-metastat high risk thu
elig treatment market penetr rate percent
may bit conserv could within ballpark sinc
elig patient popul exclud previous treat
chemotherapi model also assum success approv
apalutamid metastat modest ramp
larg owe greater competit gener zytiga xtandi
metastat set
apalutamid market us revenu revenu total apalutamid total apalutamid cancer castrat resist prostat castrat resist prostat cancer penetr market opportun apalutamid patient non-metastat castrat resist prostat cancer high risk prostat cancer patient penetr market opportun apalutamid annual per prostat cancer castrat resist prostat prostat cancer penetr market opportun apalutamid patient non-metastat prostat cancer patient nmcrpc high risk prostat cancer patient penetr market opportun annual per
johnson johnson incom growth yoy good intang research restructur gener margin expens foreign exchang gain incom expens tax adjust net litig expens asr hip pre integr pre tax ortho-clin dx divest discontinu share share ep ep growth yoy
btig cover compani mention report
appendix analyst certif import disclosur
